Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Centene Corp    CNC

News SummaryMost relevantAll newsSector newsTweets
The feature you requested does not exist. However, we suggest the following feature:

Centene : SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Centene Corp. (CNC)

share with twitter share with LinkedIn share with facebook
share via e-mail
08/21/2017 | 04:16pm CEST

NEW YORK, Aug. 21, 2017 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Centene Corp. ("Centene" or the "Company") (NYSE: CNC). Such investors are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/cnc.

The investigation concerns whether Centene and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.

On August 18, 2017, CNN.com published an article, "Pediatricians say Florida hurt sick kids to help big GOP donors", reporting that state health officials in Florida removed thousands of sick children from Children's Medical Services ("CMS"), a part of Florida Medicaid, and placed them on insurance plans owned by companies, including Centene, that cumulatively donated millions of dollars to Florida Republican Party committees. Following this news, Centene stock dropped $0.13 per share, or 0.16%, to close at $83.49 on August 18, 2017.

If you are aware of any facts relating to this investigation, or purchased shares of Centene, you can assist this investigation by visiting the firm's site: www.bgandg.com/cnc. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

View original content with multimedia:http://www.prnewswire.com/news-releases/shareholder-alert---bronstein-gewirtz--grossman-llc-announces-investigation-of-centene-corp-cnc-300506816.html

SOURCE Bronstein, Gewirtz & Grossman, LLC

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on CENTENE CORP
08/21 CENTENE : SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Announces Inves..
08/21 REMINDER : Centene Corporation's 2017 Third Quarter Financial Results Conference..
08/16 CENTENE : Sen. Cortez Masto Applauds Centene for Entering Rural Nevada Health In..
08/16 CENTENE : Rep. Rosen Comments on Centene's Decision to Enter Health Insurance Ma..
08/16 CENTENE : Sen. Heller Issues Statement on Nevada's Health Insurance
08/15 HELLER NEWS : Heller Applauds Centene's Pledge to Offer Health Plans in Nevada's..
08/15DJCENTENE : Nevada and Centene Reach Agreement on Insurance Markets
08/15 CENTENE : expands footprint in Illinois
08/15 CENTENE : Illinois Subsidiary Selected for Medicaid Managed Care Program Contrac..
08/15 CENTENE : Cortez masto applauds centene for entering rural nevada health insuran..
More news
News from SeekingAlpha
08/20 Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q2 2017 Update
08/17 Tracking David Tepper's Appaloosa Management Portfolio - Q2 2017 Update
08/17 Obamacare subsidies will continue in August
08/16 U.S. government to make August cost-sharing payments to health insurers
08/16 CBO warns on end to health subsidies
Financials ($)
Sales 2017 47 131 M
EBIT 2017 1 444 M
Net income 2017 757 M
Debt 2017 -
Yield 2017 -
P/E ratio 2017 20,34
P/E ratio 2018 17,85
Capi. / Sales 2017 0,32x
Capi. / Sales 2018 0,29x
Capitalization 14 876 M
Duration : Period :
Centene Corp Technical Analysis Chart | CNC | US15135B1017 | 4-Traders
Technical analysis trends CENTENE CORP
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 18
Average target price 93,1 $
Spread / Average Target 8,0%
EPS Revisions
Michael F. Neidorff Chairman, President & Chief Executive Officer
Jeffrey A. Schwaneke Chief Financial Officer & Executive Vice President
Ken Yamaguchi Chief Medical Officer & Executive Vice President
Mark J. Brooks Chief Information Officer & Senior Vice President
David L. Steward Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
CENTENE CORP52.63%14 876
AETNA INC24.78%52 027
ANTHEM INC34.22%51 191
HUMANA INC22.22%36 603